Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Cardiac Amyloidosis Market Size From 2025 to 2034?
In the past few years, the cardiac amyloidosis market has observed substantial growth. The market, which stands at $5.26 billion in 2024, is predicted to escalate to $5.73 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. This growth during the historic period is due to factors like an increased number of amyloidosis-related conditions, a surge in genetic mutations, heightened awareness, an upsurge in transthyretin amyloidosis cases, and a growing older population.
In the forthcoming years, a considerable expansion is anticipated in the cardiac amyloidosis market, which is projected to reach $8.03 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this growth during the forecast period include enhanced diagnosis rates, support and initiatives by the government, increased identification of genetic mutations, and patient assistance programs. The time frame of the forecast is also expected to witness key trends such as the creation of new treatments like vulrisiran, an emphasis on gene therapy research, precision medicine, progression in diagnostic technologies, and the introduction of innovative therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp
What are the Fundamental Drivers and Innovations Shaping the Cardiac Amyloidosis Market?
The expected surge in the elderly population is predicted to boost the cardiac amyloidosis market’s expansion. The term ‘elderly population’ generally refers to individuals aged 65 and above, who may require specialized healthcare and support due to age-associated alterations. Factors such as increasing life expectancy, healthcare advancements, and diminishing birth rates, contribute to the growth of the elderly population. The escalation in the number of older adults elevates the prevalence of cardiac amyloidosis since aging is a significant risk constituent for the accumulation of amyloid protein in the heart. For instance, the Population Reference Bureau, a non-profit organization based in the U.S, in January 2024 projected that the U.S population aged 65 and older would escalate from 58 million in 2022 to 82 million by 2050, signifying a 47% increase. Thus, the rise in the elderly population is expected to accelerate the growth of the cardiac amyloidosis market.
How Is the Cardiac Amyloidosis Market Segmented?
The cardiac amyloidosismarket covered in this report is segmented –
1) By Product Type: Light Chain Amyloidosis; Transthyretin Amyloidosis
2) By Treatment: Chemotherapy; Surgery; Supportive Care; Stem Cell Transplant; Targeted Therapy
3) By End-User: Hospitals; Ambulatory Surgical Centres; Clinics
Subsegments:
1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis; Primary Light Chain Amyloidosis; Secondary Light Chain Amyloidosis
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm); Wild-type Transthyretin Amyloidosis (ATTRwt)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21128&type=smp
Which Regions Are Driving the Next Phase of the Cardiac Amyloidosis Market Growth?
North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Cardiac Amyloidosis Market?
Leading corporations in the cardiac amyloidosis market are prioritizing technological advancements, such as artificial intelligence (AI)-based standalone diagnostic instruments, to facilitate early identification and better clinical outcomes for patients afflicted with this often overlooked disease. An AI-driven, software-only healthcare device developed for cardiac amyloidosis detection utilizes artificial intelligence for examining echocardiographic images and pinpointing disease indications without the need for extra hardware or extensive clinical information. For example, in November 2024, Ultromics Ltd., a health technology firm from the UK, received FDA approval for EchoGo Amyloidosis, an AI-enabled clinical instrument aimed at early detection of cardiac amyloidosis. This device is the first one in the FDA’s Total Product Lifecycle Advisory Program (TAP) that has been granted marketing authorization. EchoGo Amyloidosis utilizes artificial intelligence to scrutinize echocardiograms for disease detection from a single clip, filling a dire need for early diagnosis before the disease develops unobserved.
View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report
How Is the Cardiac Amyloidosis Market Defined and What Are Its Core Parameters?
Cardiac amyloidosis is a condition where abnormal amyloid protein deposits in the heart tissue, leading to stiffening and impaired function. This results in heart failure, arrhythmias, and other cardiovascular complications. Early diagnosis and treatment are crucial to managing symptoms and slowing disease progression.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21128
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model